PlumX Metrics
Embed PlumX Metrics

Targeting galectin-3 in inflammatory and fibrotic diseases

Trends in Pharmacological Sciences, ISSN: 0165-6147, Vol: 44, Issue: 8, Page: 519-531
2023
  • 46
    Citations
  • 0
    Usage
  • 70
    Captures
  • 0
    Mentions
  • 48
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    46
  • Captures
    70
  • Social Media
    48
    • Shares, Likes & Comments
      48
      • Facebook
        48

Review Description

Galectin (Gal)-3 is a β-galactoside-binding lectin emerging as a key player in cardiac, hepatic, renal, and pulmonary fibrosis and inflammation, respiratory infections caused by COVID-19, and neuroinflammatory disorders. Here, we review recent information highlighting Gal-3 as a relevant therapeutic target in these specific disease conditions. While a causal link was difficult to establish until now, we discuss how recent strategic breakthroughs allowed us to identify new-generation Gal-3 inhibitors with improved potency, selectivity, and bioavailability, and report their usefulness as valuable tools for proof-of-concept studies in various preclinical models of the aforementioned diseases, with emphasis on those actually in clinical stages. We also address critical views and suggestions intended to expand the therapeutic opportunities provided by this complex target.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know